Prostate Cancer Survivorship Essentials for men with prostate cancer on androgen deprivation therapy: protocol for a randomised controlled trial of a tele-based nurse-led survivorship care intervention (PCEssentials Hormone Therapy Study).

Androgen deprivation therapy (ADT) is commonly used to treat men with locally advanced or metastatic prostate cancer. Men receiving ADT experience numerous side effects and frequently report unmet supportive care needs. An essential part of quality cancer care is survivorship care. To date, an optimal effective approach to survivorship care for men with prostate cancer on ADT has not been described. This protocol describes a randomised trial of tele-based nurse-led survivorship that addresses this knowledge gap: (1) determine the effectiveness of a nurse-led survivorship care intervention (PCEssentials), relative to usual care, for improving health-related quality of life (HR-QoL) in men with prostate cancer undergoing ADT and (2) evaluate PCEssentials implementation strategies and outcomes, including cost-effectiveness, compared with usual care.

This is an effectiveness-implementation hybrid (type 1) trial with participants randomised to one of two arms: (1) minimally enhanced usual care and (2) nurse-led prostate cancer survivorship essentials (PCEssentials) delivered over four tele-based sessions, with a booster session 5 months after session 1. Eligible participants are Australian men with prostate cancer commencing ADT and expected to be on ADT for a minimum of 12 months. Participants are followed up at 3, 6 and 12 months postrecruitment. Primary outcomes are HR-QoL and self-efficacy. Secondary outcomes are psychological distress, insomnia, fatigue and physical activity. A concurrent process evaluation with participants and study stakeholders will be undertaken to determine effectiveness of delivery of PCEssentials.

Ethics approval was obtained from the Metro South Health HREC (HREC/2021/QMS/79429). All participants are required to provide written informed consent. Outcomes of this trial will be published in peer-reviewed journals. The findings will be presented at conferences and meetings, local hospital departments, participating organisations/clinical services, and university seminars, and communicated at community and consumer-led forums.

ACTRN12622000025730.

BMJ open. 2024 Mar 23*** epublish ***

Anna Green, Robert U Newton, David P Smith, Haitham Tuffaha, Daniel A Galv√£o, Peter Heathcote, Manish I Patel, David Christie, Sam Egger, Sally Am Sara, Nicole Heneka, Suzanne K Chambers, Jeff Dunn

Centre for Health Research, University of Southern Queensland, Springfield Central, Queensland, Australia ., Exercise Medicine Research Institute, Edith Cowan University, Joondalup, Western Australia, Australia., The Daffodil Centre, a joint venture with Cancer Council NSW, The University of Sydney, Sydney, New South Wales, Australia., The University of Queensland, Saint Lucia, Queensland, Australia., Brisbane Urology Clinic, Brisbane, Queensland, Australia., University of Sydney, Sydney, New South Wales, Australia., Genesiscare, Tugun, Queensland, Australia., Prostate Cancer Foundation of Australia, St Leonards, New South Wales, Australia., Centre for Health Research, University of Southern Queensland, Springfield Central, Queensland, Australia., Australian Catholic University, Brisbane, Queensland, Australia.